All Stories

  1. Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community
  2. Preface to Special Edition: Microbiome, Inflammation and Cancer
  3. GI highlights from the literature
  4. 3D printed rectal swabs for assessing the gut microbiome, metabolome and inflammation
  5. Inflammation, oxidative stress and gut microbiome perturbation: A narrative review of mechanisms and treatment of the alcohol hangover
  6. Alcohol-Associated liver disease: Emerging therapeutic strategies
  7. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
  8. FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease
  9. FRI-286 Muscle function and walking time are associated with better quality of life in MASLD patients
  10. OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling
  11. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression
  12. WED-546 Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males
  13. P126 Gut microbiota composition and functionality in a thiopurine-naïve cohort of inflammatory bowel disease (IBD) can differentiate between clinical outcomes
  14. P61 Ethnic differences in ulcerative colitis: a study of 15,053 South Asian and white patients using the UK IBD bioresource
  15. Decision
  16. The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
  17. Authors' reply to letter: He who controls Clostridia and Bacteroidia controls the gut microbiome: The concept of targeted probiotics to restore the balance of keystone taxa in irritable bowel syndrome
  18. GI highlights from the literature
  19. Mo1870 CONSISTENT APPROACH TO IBD TREATMENT ACROSS SOUTH ASIAN AND WHITE ETHNICITIES IN THE UK DESPITE PHENOTYPIC VARIATIONS: A STUDY OF 33,157 PATIENTS USING THE IBD BIORESOURCE
  20. Sa1871 THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOTA IN A TREATMENT NAIVE INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) CAN ACCURATELY DIFFERENTIATE IBD PHENOTYPE.
  21. Sa1889 3D PRINTED RECTAL SWABS FOR ASSESSING THE GUT MICROBIOME, METABOLOME, AND INFLAMMATION
  22. Sa1927 ANTIBIOTIC TREATMENT PROMOTES THE INTESTINAL COLONISATION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS BY KILLING MEMBERS OF THE GUT MICROBIOTA AND DECREASING NUTRIENT COMPETITION
  23. Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
  24. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond
  25. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridioides difficileinfection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society...
  26. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS...
  27. Lyophilized fecal microbiome transfer for primary Clostridioides difficile infection: a multicenter randomized controlled trial (DONATE Study)
  28. Overview of the second edition of the joint British Society of Gastroenterology and Healthcare Infection Society faecal microbiota transplant guidelines, 2024
  29. The beneficial hepatic effects of glucagon‐like peptide 1 receptor agonists in patients with diabetes and metabolic dysfunction‐associated steatotic liver disease are independent of weight loss
  30. GI highlights from the literature
  31. A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females
  32. Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus
  33. Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial
  34. OP07 Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResource
  35. P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis
  36. Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?
  37. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
  38. Liver sinusoidal cells in the diagnosis and treatment of liver diseases: Role of hepatic stellate cells
  39. Evaluating Protocols for Reproducible Targeted Metabolomics by NMR
  40. Pharmacotherapy in Managing Alcohol-Use Disorder
  41. The role of faecal microbiota transplantation in chronic noncommunicable disorders
  42. GI highlights from the literature
  43. Gut microbiota and immunotherapy of renal cell carcinoma
  44. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
  45. THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
  46. Alcohol Minimum Unit Pricing Reduces Alcohol-Specific Hospitalizations and Deaths
  47. Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA<...
  48. A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies
  49. O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease
  50. P18 A 5 sit-to-stand test may identify NAFLD patients at higher risk for worse clinical outcomes
  51. P26 Exploring the association between quality of life, diet, physical activity, and binge eating disorder in NAFLD patients in a tertiary centre of care
  52. Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites
  53. GI highlights from the literature
  54. Faecal microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial
  55. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
  56. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
  57. Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease
  58. P79 COVID-19 vaccine-induced antibody response is associated with oral microbiota composition in patients with inflammatory bowel disease, cirrhosis, and liver transplantation
  59. P325 Colonoscopy surveillance in primary sclerosing cholangitis patients during the COVID-19 pandemic – a tertiary centre experience
  60. Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial
  61. Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial
  62. Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease
  63. Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients
  64. Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation
  65. The Impact of Proportional Dietary Carbohydrate and Fat Content on Type 2 Diabetes and NAFLD
  66. POS0423 PLASMA METABOLOMIC PROFILES OF PATIENTS WITH ACTIVE PERIPHERAL PSORIATIC ARTHRITIS CAN DIFFERENTIATE TREATMENT RESPONDERS FROM FAILURES: EXPLORATORY FINDINGS FROM THE FLORA TRIAL
  67. A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease
  68. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
  69. GI highlights from the literature
  70. Increased risk of cirrhosis in post-menopausal women with NAFLD
  71. Tu1866 SALIVARY MICROBIOTA COMPOSITION IS ASSOCIATED WITH ANTIBODY RESPONSE FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE, CIRRHOSIS AND LIVER TRANSPLANTATION
  72. Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
  73. Screening for NAFLD—Current Knowledge and Challenges
  74. The gastrointestinal status of healthy adults: a post hoc assessment of the impact of three distinct probiotics
  75. GI highlights from the literature
  76. Antibiotics promote intestinal growth of carbapenem-resistantEnterobacteriaceaeby enriching nutrients and depleting microbial metabolites
  77. Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community
  78. Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
  79. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
  80. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition
  81. GI highlights from the literature
  82. Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome
  83. Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply
  84. Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans
  85. GI highlights from the literature
  86. 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
  87. 614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
  88. Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel
  89. Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection
  90. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
  91. UEG Week 2022 Poster Presentations
  92. Polymorphic microbes: a new emerging hallmark of cancer
  93. New insights into host‐microbiome crosstalk in psoriatic skin
  94. Recent Findings in the Gut-Liver Axis and Associated Disease Therapy
  95. GI highlights from the literature
  96. Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease
  97. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
  98. A study evaluating outcomes of a virtual specialist liver cirrhosis clinic
  99. Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus
  100. Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls
  101. Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD
  102. Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study
  103. Intestinal microbiota transplantation: do not forget the metabolites
  104. Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases
  105. Fecal bile acid profiles predict recurrence in patients with primary Clostridioides difficile infection
  106. GI highlights from the literature
  107. P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function
  108. The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
  109. Identifying transient and stable bacteria- metabolite interactions from longitudinal multi-omics data
  110. Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome
  111. 643: CLINICAL AND ECONOMICAL EVALUATION OF COMMUNITY-BASED PREVENTATIVE SCREENING STRATEGIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE
  112. 681: FACTORS ASSOCIATED WITH INCREASED GUT PERMEABILITY AND SEVERITY OF LIVER DISEASE IN DIABETIC PATIENTS WITH NAFLD
  113. 894: RELATIVE CHANGE OF ENTEROCOCCUS FAECIUM, SELECTED COMMENSAL BACTERIA AND CYTOKINES ARE SEEN IN PATIENTS COLONIZED WITH MULTIDRUG-RESISTANT ORGANISMS WHO UNDERGO INTESTINAL MICROBIOTA TRANSPLANTATION.
  114. Mo1589: IMPACT ON GUT MICROBIAL METABOLITES FROM A 6-MONTH DOUBLEBLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS
  115. Sa1657: NEW LINKS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOME SUGGEST A STRONGER ROLE OF THE GUT-JOINT AXIS
  116. Su1601: INTESTINAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIODIOIDES DIFFICILE INFECTION IS ASSOCIATED WITH RESTORATION OF MICROBIAL ARYLSULFATASES AND SULFATIDE DEGRADATION
  117. Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
  118. Tu1312: EXAMINING THE CORRELATION OF HISTOLOGICAL FEATURES OF NAFLD WITH A POLYMETABOLIC RISK SCORE FOR PREDICTING PATIENTS WITH NAFLD
  119. Impact of gastrointestinal surgery upon the gut microbiome: A systematic review
  120. How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection
  121. GI highlights from the literature
  122. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
  123. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition
  124. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
  125. The potential of fecal microbiota transplantation in oncology
  126. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
  127. GI highlights from the literature
  128. A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
  129. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease
  130. Clostridioides difficile: innovations in target discovery and potential for therapeutic success
  131. Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD)
  132. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series
  133. GI highlights from the literature
  134. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
  135. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
  136. Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
  137. GI highlights from the literature
  138. Binge‐eating disorder is associated with an unfavorable body mass composition in patients with non‐alcoholic fatty liver disease
  139. Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India
  140. Rapid resolution of COVID-19 after faecal microbiota transplantation
  141. GI highlights from the literature
  142. 739 DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE
  143. 811 FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL
  144. Fr571 A DISTINCTIVE SIGNATURE OF FECAL BILE ACIDS AND OTHER NOVEL METABOLITES ACCOMPANYING RECURRENCE AFTER PRIMARY CLOSTRIDIOIDES DIFFICILE INFECTION
  145. Fr573 ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE
  146. Sa022 A HIGH-FIBER LOW-FAT DIET INCREASES FECAL LEVELS OF LITHOCHOLIC ACID DERIVATIVE 3-KETOCHOLANIC ACID
  147. Su541 RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION
  148. SARS-CoV-2 vaccines and donor recruitment for FMT
  149. Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice
  150. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections
  151. GI highlights from the literature
  152. Fecal Microbiota Transplantation: The Evolving Risk Landscape
  153. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity
  154. Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults
  155. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?
  156. NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials
  157. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
  158. Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial
  159. P307 FMT-associated alterations in the TCR repertoire of patients with severe or fulminant clostridioides difficile infection
  160. Non-Alcoholic Fatty Liver Disease and Vascular Disease
  161. Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
  162. The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173)
  163. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis
  164. GI highlights from the literature
  165. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection
  166. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection
  167. A Guide to the Gut Microbiome and its Relevance to Critical Care
  168. Letter: intestinal microbiota transfer—updating the nomenclature to increase acceptability
  169. Reply to Woodworth, et al.
  170. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
  171. Abstract Supplement ACR Convergence 2020
  172. S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection
  173. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites
  174. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?
  175. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders
  176. High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
  177. Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis
  178. Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms
  179. Letter: faecal microbiota transplantation for IBS
  180. Letter: liver disease and COVID‐19—not the perfect storm
  181. GI highlights from the literature
  182. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
  183. Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31
  184. 1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION
  185. 121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION
  186. 644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
  187. Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION
  188. Sa1923 IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOTA, A PHENOMIC STUDY
  189. Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY
  190. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel
  191. Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?
  192. GI highlights from the literature
  193. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients
  194. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being
  195. GI highlights from the literature
  196. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy
  197. The gut microbiome: what every gastroenterologist needs to know
  198. Case-control study of recurrent Extended-Spectrum Beta Lactamase Enterobacteriaceae Urinary Tract Infections (ESBL UTIs): the management challenges
  199. Cohort study of Faecal Microbiota Transplantation for patient’s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates
  200. Faecal microbiota transplantations and urinary tract infections – Authors' reply
  201. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease
  202. P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis
  203. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?
  204. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
  205. Antibiotic therapy and outcome from immune-checkpoint inhibitors
  206. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non‐alcoholic fatty liver disease—authors' reply
  207. 185 Evaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection
  208. 837 Short Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection
  209. Posters (Abstracts 289–2348)
  210. Guidelines - Stool banking for faecal microbiota transplantation in clinical practice
  211. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications
  212. Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: ‘A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enter...
  213. BAUS 2019 Abstract Book
  214. Recurrent bacteraemia following variceal haemorrhage
  215. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation
  216. 621 – Fecal Microbiota Transplantation for the Treatment of Obesity: A Randomized, Placebo-Controlled Pilot Trial
  217. 7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation
  218. Mo1953 – Growth Inhibition of Clostridioides Difficile by Short and Medium Chain Fatty Acids
  219. Sa1924 – Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model
  220. MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY
  221. PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis
  222. SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD
  223. THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?
  224. THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume
  225. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non‐alcoholic fatty liver disease – authors’ reply
  226. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
  227. Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality
  228. Current and future targets for faecal microbiota transplantation
  229. Current and future pharmacological therapies for managing cirrhosis and its complications
  230. Liver Biopsy
  231. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection
  232. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial
  233. The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease
  234. Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease
  235. 1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae
  236. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota
  237. Non-alcoholic fatty liver disease and cardiovascular risk: an update
  238. Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award
  239. Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines
  240. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease
  241. Posters (Abstracts 301–2389)
  242. Publisher’s Note: Poster Abstract
  243. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway
  244. The implementation of omics technologies in cancer microbiome research
  245. Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study
  246. Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant
  247. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
  248. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
  249. 0503 - A novel route for controlling Clostridioides difficile growth via bile acid and short chain fatty acid modulation
  250. Clostridium difficile infection and antibiotic-associated diarrhoea
  251. IDDF2018-ABS-0056 Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study
  252. PWE-052 Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study
  253. Letter: improvements in mental health after faecal microbiota transplantation—an underexplored treatment‐related benefit?
  254. 24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation
  255. 25 - Microbiome and Metabolic Markers of Clostridium Difficile Recurrance
  256. Tu1894 - Potential Motivators and Deterents for Stool Donors: A Multicenter Study
  257. A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease
  258. Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia‐related portal vein thrombosis
  259. P141 Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study
  260. Posters (Abstracts 264-2239)
  261. Comparative epidemiology of Clostridium difficile infection: England and the USA
  262. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial
  263. Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality
  264. PWE-093 Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine: histological images in patients with non-alcoholic fatty liver disease
  265. PWE-094 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease
  266. Anticoagulation in chronic liver disease
  267. Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes
  268. National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK
  269. The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease
  270. Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?
  271. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
  272. OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom
  273. PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?
  274. Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces
  275. Cardiology
  276. Clinical haematology and oncology
  277. Clinical sciences
  278. Dermatology
  279. Endocrinology
  280. Gastroenterology
  281. Geriatric medicine
  282. Infectious diseases and GUM
  283. Nephrology
  284. Neurology
  285. Ophthalmology
  286. Psychiatry
  287. Respiratory medicine
  288. Rheumatology
  289. Obstacles to establishing an NHS faecal transplant programme
  290. Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors’ reply
  291. Weight loss in a man from West Africa
  292. Global patterns of cardia and non-cardia gastric cancer incidence in 2012
  293. Case 25-2014: A Man with Ulcerative Colitis and Bloody Diarrhea
  294. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection
  295. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation
  296. Low Incidence Of Venous Thromboembolism In Mobile Populations
  297. Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature
  298. P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS
  299. MRCP Part 1: 400 BOFs
  300. Cardiology
  301. Clinical pharmacology, therapeutics and toxicology
  302. Clinical sciences
  303. Dermatology
  304. Endocrinology
  305. Gastroenterology
  306. Haematology and oncology
  307. Neurology
  308. Ophthalmology
  309. Psychiatry
  310. Renal medicine
  311. Respiratory medicine
  312. Rheumatology
  313. Tropical, infectious and sexually transmitted diseases
  314. Shoulder pain and dysphagia with an unexpected cause
  315. Ascites